Who is sponsoring NCT07042724?

NCT07042724 is sponsored by Universita di Verona.

What drugs are being tested in NCT07042724?

Interventions in NCT07042724: Physical exercise and nutrition intervention for the neoadjuvant setting, Physical exercise and nutrition for the adjuvant setting, Health educational material.

What condition does NCT07042724 study?

NCT07042724 studies Lung Cancer (NSCLC).

Is NCT07042724 still recruiting?

NCT07042724 is currently recruiting now. Last updated 29 June 2025.

Last reviewed 2025-06-29 · How we verify

NCT07042724: STARLighT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise and Nutrition on Early-stage NSCLC Outcomes: the STARLighT Study

Recruiting now NA Last updated 29 June 2025

What this trial tests

NA trial testing Physical exercise and nutrition intervention for the neoadjuvant setting in Lung Cancer (NSCLC) in 324 participants. Currently enrolling.

Timeline

1 September 2025

Primary endpoint
30 April 2030

30 April 2030

Quick facts

Lead sponsor	Universita di Verona
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	324
Start date	1 September 2025
Primary completion	30 April 2030
Estimated completion	30 April 2030
Sites	1 location across Italy

Drugs / interventions tested

Physical exercise and nutrition intervention for the neoadjuvant setting
Physical exercise and nutrition for the adjuvant setting
Health educational material

Conditions studied

Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →

Sponsor

Universita di Verona — full company profile →

Who can join

18 and older, any sex, with Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The general goal of the STARLighT study is to test whether a structured physical exercise and nutritional intervention significantly impacts clinical outcomes in patients with early-stage lung cancer. The main questions it aims to answer are: * Can structured physical exercise and nutrition intervention positively modify the pathological complete response in patients with early-stage lung cancer undergoing neoadjuvant treatments? * Can structured physical exercise and nutrition intervention positively influence disease-free survival in patients with early-stage lung cancer undergoing adjuvant treatments compared to usual care? This study will recruit two cohorts of patients. Cohort A will accrue patients who are candidates for neoadjuvant treatment and offer the opportunity to participate in a structured physical exercise and nutritional program, lasting the entire period of anticancer treatment. Cohort B will accrue patients who are candidates for adjuvant treatments. Patients will be randomized to receive 6 months of structured physical exercise and nutritional intervention or standard of care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Telehealth-delivered exercise and nutrition intervention to improve outcomes in patients with early stage non-small cell lung cancer: protocol for the multicentre STARLighT phase II (neoadjuvant) and phase III (adjuvant) trial.
Avancini A, Giannarelli D, Ugel S, Mafficini A, et al · · 2026 · PMID 41526018 · DOI 10.1136/bmjopen-2025-108080

Verify or expand the search:

Other recruiting trials for Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07379476 — Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
NCT07120282 — Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC · Phase 2 · recruiting

Other Universita di Verona trials

Trials by the same sponsor.

NCT07393919 — Discontination of Antidepressants in Remitted Depression · Phase 4 · not yet recruiting
NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
NCT07119827 — Personality Traits as a Variable in the Recovery of Patients With Acquired Brain Injury · recruiting
NCT07209306 — WHO Psychological Interventions for Mental Health Outcomes in Migrants Resettled in Italy: the ADVANCE Trial · NA · recruiting
NCT06926348 — Assessment of Usability and Preliminary Effectiveness of a Digital Sleep Aid in an Italian Sample · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07042724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universita di Verona
Last refreshed: 29 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07042724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing